Integration of amyloid-β oligomerization tendency as a plasma biomarker in Alzheimer's disease diagnosis

Introduction There has been significant development in blood-based biomarkers targeting amyloidopathy of Alzheimer's disease (AD). However, the guidelines for integrating such biomarkers into AD diagnosis are still inadequate. Multimer Detection System-Oligomeric Amyloid-beta (MDS-OA beta) as a plasma biomarker detecting oligomerization tendency is available in the clinical practice.Main text We suggest how to interpret the results of plasma biomarker for amyloidopathy using MDS-OA beta with neuropsychological test, brain magnetic resonance imaging (MRI), and amyloid PET for AD diagnosis. Combination of each test result differentiates various stages of AD, other neurodegenerative diseases, or cognitive impairment due to the causes other than neurodegeneration.Discussion A systematic interpretation strategy could support accurate diagnosis and staging of AD. Moreover, comprehensive use of biomarkers that target amyloidopathy such as amyloid PET on brain amyloid plaque and MDS-OA beta on amyloid-beta oligomerization tendency can complement to gain advanced insights on amyloid-beta dynamics in AD.